Gritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine Combination
“We are privileged to establish this collaboration with NCI and Dr. Rosenberg, a pioneer of cancer immunotherapy and an expert in cell therapy,” said Andrew Allen, M.D., Ph.D, Co-founder, President & Chief Executive Officer of Gritstone bio. “To date, cell therapy’s success in treating blood cancers has not translated to the more common solid tumors. There is a mechanistic synergy in having cell therapy and cancer vaccines in combination. We are thrilled to test this hypothesis in patients in collaboration with a leader in the cell therapy field. We look forward to collaborating with Dr. Rosenberg and his team to generate proof-of-concept data from this promising study.”
Share:
More News
“We are pleased to evaluate the clinical combination of IDE892 with RG6505 in MTAP-deleted RAS-mutant PDAC,” said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences. “This collaboration aligns with our broader clinical strategy to evaluate rational combinations with assets in our MTAP-deletion portfolio, and there remains especially high
“In the first reported data from the clinical combinations of our PRMT5 inhibitor vopimetostat and RAS(ON) inhibitors, we saw extremely encouraging early results, with 92% of patients with PDAC in the vopimetostat plus daraxonrasib arm achieving an objective response, supporting the preclinical data showing synergistic activity of PRMT5 + RAS
“Non-small cell lung cancer is the most prevalent lung disease with more than 8,000 patients in the U.S. diagnosed each year with KRAS G12D-mutations. Receiving Fast Track designation for VS-7375 reinforces both the significant unmet need and the potential of VS-7375 to improve outcomes for patients with KRAS G12D-mutated lung
“KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years,” said John Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine, Research & Development, Johnson & Johnson. “We believe the proprietary Firelink™ platform will overcome